Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-90. (canceled)

Claim 91. (previously presented) A compound of formula (I):

\[
\begin{array}{c}
\text{O} \\
\text{R}_1 \\
\text{R}_2 \\
\text{R}_3 \\
\text{Ra} \\
\text{N} \\
\text{Rb} \\
\text{n} \\
\end{array}
\]

(i)

wherein

\( R_a \) and \( R_b \) together with the nitrogen to which they are attached form a 6 membered heterocycle optionally including up to 3 additional heteroatoms;

\( n \) is 0-4;

\( R_1 \) is hydrogen or halo;

one of \( R_2 \) and \( R_3 \) is \( G \) and the other is hydrogen or halo;

\( G \) is

\[
\begin{array}{c}
\text{L}_3 \\
\text{C} \\
\text{R}_7 \\
\text{L}_6 \\
\text{N} \\
\text{L}_7 \\
\text{R}_{10} \\
\end{array}
\]

(ii)

\( L_3 \) is phenyl or naphthyl;

\( L_6 \) is \( C_{1-5} \) alkylene;

\( L_7 \) is \( C_{1-5} \) alkylene or absent;
R₇ is H, hydroxyl, halo, or C₂₋₆alkoxy or is absent where the carbon linking L₆ and L₇ participates in a double bond;

R₁₀ is H, C₁₋₈alkyl, C₃₋₈alkenyl, C₃₋₇cycloalkyl, (C₃₋₇cycloalkyl)C₁₋₆alkylene, (C₂₋₁₃heterocyclyl)C₁₋₆alkylene, or (phenyl)C₁₋₆alkylene;

wherein each of the above alkyl, alkenyln, alkylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be unsubstituted or substituted with between 1 and 3 substituents independently selected from halo, amino, nitro, hydroxyl, and C₁₋₃alkyl;

or a pharmaceutically acceptable salt thereof.

Claim 92. (previously presented) A compound of claim 91, wherein NR₉R₁₀ taken together form piperidyl or methylpiperidyl.

Claim 93. (previously presented) A compound of claim 92, wherein NR₉R₁₀ taken together form piperidyl.

Claim 94. (previously presented) A compound of claim 91, wherein R₂ is G.

Claim 95. (previously presented) A compound of claim 91, wherein R₃ is G.

Claim 96. (previously presented) A compound of claim 91, wherein n is between 1 and 4, inclusive.

Claim 97. (previously presented) A compound of claim 96, wherein n is 1.

Claim 98. (previously presented) A compound of claim 91, wherein L₃ is phenylene.

Claim 99. (previously presented) The compound 1-[3-[2"-(1-isopropyl-piperidin-4-yl)-biphenyl-4-yloxy]-propyl]-piperidine.

Claim 100. (previously presented) A pharmaceutical composition comprising a compound of claim 91 or 99 and a pharmaceutically acceptable excipient.
Claim 101. (previously presented) A compound of claim 91 or 99, isotopically-labelled to be detectable by positron emission tomography or single-photon emission computed tomography.

Claim 102. (previously presented) A method of inhibiting histamine H₃ receptor activity in a subject, comprising administering an effective amount of a compound of claim 91 or 99 to a subject in need of such inhibition of histamine H₃ receptor activity.

Claim 103. (currently amended) A method of treating a subject having a disease or condition modulated by histamine H₃ receptor activity, comprising administering to the subject a therapeutically effective amount of a compound of claim 91 or 99 wherein said disease or condition is selected from the group consisting of sleep/wake disorders, arousal/vigilance disorders, migraine, asthma, dementia, mild cognitive impairment (pre-dementia), Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorders, learning disorders, memory retention disorders, schizophrenia, nasal congestion, allergic rhinitis, and upper airway allergic response.

Claim 104. (canceled)

Claim 105. (canceled)

Claim 106. (canceled)

Claim 107. (canceled)

Claim 108. (canceled)

Claim 109. (canceled)

Claim 110. (canceled)

Claim 111. (currently amended) A method according to claim 103 for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 91 or 99.
Claim 112. (currently amended) A method according to claim 103 for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of claim 91 or 99.

Claim 113. (currently amended) A method according to claim 103 for treating one or more disorders or conditions selected from the group consisting of dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, schizophrenia, depression, manic disorders, bipolar disorders, and learning and memory disorders, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 91 or 99.

Claim 114. (currently amended) A method according to claim 103 for treating or preventing upper airway allergic response, nasal congestion, or allergic rhinitis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 91 or 99.

Claim 115. (previously presented) A method for studying disorders mediated by the histamine H3 receptor, comprising using an \(^{18}\text{F}\)-labeled compound of claim 91 as a positron emission tomography (PET) molecular probe.